{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:29:31Z","timestamp":1787567371611,"version":"build-2736575974"},"reference-count":126,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>\n                    The development of new cancer therapies with greater efficacy has reduced mortality for many cancers, as well as improving survivorship. However, for some cancer treatments, this has uncovered unintended cardiotoxicity during or after treatment, and cardiovascular disease has emerged as a leading cause of mortality in some cancer survivors. This may occur because many of the same growth factor signaling pathways that lead to tumor growth are also critical for maintaining normal heart function. A class IA phosphoinositide 3-kinase, PI3K(p110\n                    <jats:italic>\u03b1<\/jats:italic>\n                    ), is a critical regulator of normal heart biology, function and exercise-induced cardiac protection, but is also mutated\/increased in some cancer types. In this review, we discuss the dual role of PI3K(p110\n                    <jats:italic>\u03b1<\/jats:italic>\n                    ) signaling in cancer and the heart. The paradox being, that inhibiting PI3K(p110\n                    <jats:italic>\u03b1<\/jats:italic>\n                    ) in a setting of some cancer types would be beneficial for halting\/slowing tumor progression but could also damage heart muscle cells. Exercise and PI3K(p110\n                    <jats:italic>\u03b1<\/jats:italic>\n                    ) has beneficial effects on heart function via cardiac excitation and contraction, mitochondrial adaptations, cellular stress responses to promote survival, preventing cell death and cardiac fibrosis. We contrast this to the chemotherapy, doxorubicin, which is crucial for the treatment of many cancers but negatively impacts many of the beneficial effects of exercise and PI3K(p110\n                    <jats:italic>\u03b1<\/jats:italic>\n                    ). Doxorubicin's clinical efficacy is limited by dose-dependent cardiotoxicity including cardiomyopathy, atrial fibrillation, and heart failure. A summary of reported cardiovascular effects in clinical trials using PI3K inhibitors is also provided. Finally, we discuss some of the current and emerging approaches to mitigate cancer therapy-induced cardiotoxicity including pharmacological interventions, gene therapy and dietary approaches based on preclinical studies. Advances in the field are likely to come from continued refinement of cardiotoxicity models, the investigation of targeting molecular pathways and targets with relevant primary endpoints for both cancer and heart function, and collaborative research with discovery\/preclinical scientists and clinicians.\n                  <\/jats:p>","DOI":"10.3389\/fcvm.2026.1891148","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:08:26Z","timestamp":1787562506000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Understanding the distinct role of PI3K(p110\u03b1) in cancer and the heart to prevent chemotherapy-induced cardiotoxicity: mechanisms and therapeutic opportunities"],"prefix":"10.3389","volume":"13","author":[{"given":"Teleah G.","family":"Belkin","sequence":"first","affiliation":[{"name":"Baker Heart and Diabetes Institute","place":["Melbourne, VIC, Australia"]},{"name":"School of Translational Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University","place":["Melbourne, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yow Keat","family":"Tham","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute","place":["Melbourne, VIC, Australia"]},{"name":"School of Translational Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University","place":["Melbourne, VIC, Australia"]},{"name":"Baker Department of Cardiovascular Research, Translation and Implementation, La Trobe University","place":["Bundoora, VIC, Australia"]},{"name":"Baker Department of Cardiometabolic Health, The University of Melbourne","place":["Melbourne, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J.","family":"Edgley","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of Melbourne","place":["Melbourne, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"McMullen","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute","place":["Melbourne, VIC, Australia"]},{"name":"Baker Department of Cardiovascular Research, Translation and Implementation, La Trobe University","place":["Bundoora, VIC, Australia"]},{"name":"Baker Department of Cardiometabolic Health, The University of Melbourne","place":["Melbourne, VIC, Australia"]},{"name":"Heart Research Institute, The University of Sydney","place":["Newtown, NSW, Australia"]},{"name":"Department of Physiology, Monash University","place":["Melbourne, VIC, Australia"]},{"name":"Monash Alfred Baker Centre for Cardiovascular Research, Faculty of Medicine, Nursing and Health Sciences, Monash University","place":["Melbourne, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s12672-025-02198-8","article-title":"Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy","volume":"16","author":"Zafar","year":"2025","journal-title":"Discov Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e926","DOI":"10.1161\/CIR.0000000000001308","article-title":"Cardiovascular toxicity in patients treated for childhood cancer: a scientific statement from the American Heart Association","volume":"151","author":"Ryan","year":"2025","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3390\/ph18091399","article-title":"Cardiotoxicity induced by anticancer therapies: a call for integrated cardio-oncology practice","volume":"18","author":"Ciappina","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s10741-025-10531-0","article-title":"Cancer therapy-induced cardiotoxicity: mechanisms and mitigations","volume":"30","author":"Shil","year":"2025","journal-title":"Heart Fail Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jaccao.2024.07.017","article-title":"Cardiovascular considerations before cancer therapy and JACC: cardioOncology expert panel recommendations","volume":"6","author":"Raisi-Estabragh","year":"2024","journal-title":"JACC CardioOncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4274\/ijca.2025.39358","article-title":"Cardiac toxicity of cancer therapies: mechanisms, surveillance, and clinical implications","volume":"11","author":"Sudeep Edpuganti","year":"2025","journal-title":"Int J Cardiovasc Acad"},{"key":"B12","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.jshs.2020.11.009","article-title":"IGF1-PI3K-induced Physiological cardiac hypertrophy: implications for new heart failure therapies, biomarkers, and predicting cardiotoxicity","volume":"10","author":"Bass-Stringer","year":"2021","journal-title":"J Sport Health Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"101023","DOI":"10.1016\/j.jshs.2025.101023","article-title":"Reduced PI3K(p110\u03b1) induces atrial myopathy, and PI3K-related lipids are dysregulated in athletes with atrial fibrillation","volume":"14","author":"Bass-Stringer","year":"2025","journal-title":"J Sport Health Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1073\/pnas.0606663104","article-title":"Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy","volume":"104","author":"McMullen","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B15","doi-asserted-by":"publisher","first-page":"12355","DOI":"10.1073\/pnas.1934654100","article-title":"Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy","volume":"100","author":"McMullen","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-981-10-4304-8_12","article-title":"The IGF1-PI3K-Akt signaling pathway in mediating exercise-induced cardiac hypertrophy and protection","volume":"1000","author":"Weeks","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1161\/CIRCHEARTFAILURE.112.966622","article-title":"Phosphoinositide 3-kinase p110\u03b1 is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction","volume":"5","author":"Weeks","year":"2012","journal-title":"Circ Heart Fail"},{"key":"B18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1750-3639.2004.tb00080.x","article-title":"Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas","volume":"14","author":"Mizoguchi","year":"2004","journal-title":"Brain Pathol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrm3290","article-title":"PI3K signalling: the path to discovery and understanding","volume":"13","author":"Vanhaesebroeck","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1242596","DOI":"10.3389\/fcvm.2023.1242596","article-title":"Anthracycline-induced cardiotoxicity: mechanisms, monitoring, and prevention","volume":"10","author":"Qiu","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0955-0674(99)80029-5","article-title":"Signalling through phosphoinositide 3-kinases: the lipids take centre stage","volume":"11","author":"Leevers","year":"1999","journal-title":"Curr Opin Cell Biol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0968-0004(97)01061-X","article-title":"Phosphoinositide 3-kinases: a conserved family of signal transducers","volume":"22","author":"Vanhaesebroeck","year":"1997","journal-title":"Trends Biochem Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","article-title":"The phosphoinositide 3-kinase pathway","volume":"296","author":"Cantley","year":"2002","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/sj.onc.1207278","article-title":"Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion","volume":"23","author":"Sch\u00e4fer","year":"2004","journal-title":"Oncogene"},{"key":"B26","doi-asserted-by":"publisher","first-page":"7678","DOI":"10.1158\/0008-5472.CAN-04-2933","article-title":"Mutation of the PIK3CA gene in ovarian and breast cancer","volume":"64","author":"Campbell","year":"2004","journal-title":"Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/82_2010_68","article-title":"Oncogenic mutations of PIK3CA in human cancers","volume":"347","author":"Samuels","year":"2011","journal-title":"Curr Top Microbiol Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"15259","DOI":"10.1073\/pnas.1205508109","article-title":"Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110\u03b1 (PIK3CA)","volume":"109","author":"Burke","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41467-023-35789-6","article-title":"Oncogenic mutations of PIK3CA lead to increased membrane recruitment driven by reorientation of the ABD, p85 and C-terminus","volume":"14","author":"Jenkins","year":"2023","journal-title":"Nat Commun."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1038\/oncsis.2013.38","article-title":"Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R","volume":"2","author":"Meyer","year":"2013","journal-title":"Oncogenesis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12943-017-0660-5","article-title":"PIK3CA Hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models","volume":"16","author":"Nisa","year":"2017","journal-title":"Mol Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1073\/pnas.0408864102","article-title":"Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic","volume":"102","author":"Kang","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B33","doi-asserted-by":"publisher","first-page":"10992","DOI":"10.1158\/0008-5472.CAN-05-2612","article-title":"Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells","volume":"65","author":"Isakoff","year":"2005","journal-title":"Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"18443","DOI":"10.1073\/pnas.0508988102","article-title":"The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells","volume":"102","author":"Zhao","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B35","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.cell.2014.03.027","article-title":"Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function","volume":"157","author":"Papa","year":"2014","journal-title":"Cell"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1111\/febs.12175","article-title":"Mouse models of PIK3CA mutations: one mutation initiates heterogeneous mammary tumors","volume":"280","author":"Koren","year":"2013","journal-title":"FEBS J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1073\/pnas.0712169105","article-title":"Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms","volume":"105","author":"Zhao","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B38","doi-asserted-by":"publisher","first-page":"9739","DOI":"10.1073\/pnas.0804123105","article-title":"Class 1A PI3K regulates vessel integrity during development and tumorigenesis","volume":"105","author":"Yuan","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.jacc.2015.07.025","article-title":"Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors","volume":"66","author":"Li","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1042\/BST20190845","article-title":"Class IA PI3K regulatory subunits: p110-independent roles and structures","volume":"48","author":"Fox","year":"2020","journal-title":"Biochem Soc Trans"},{"key":"B41","doi-asserted-by":"publisher","first-page":"6584","DOI":"10.1002\/j.1460-2075.1996.tb01049.x","article-title":"The Drosophila phosphoinositide 3-kinase Dp110 promotes cell growth","volume":"15","author":"Leevers","year":"1996","journal-title":"EMBO J"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1093\/emboj\/19.11.2537","article-title":"The conserved phosphoinositide 3-kinase pathway determines heart size in mice","volume":"19","author":"Shioi","year":"2000","journal-title":"EMBO J"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s00204-015-1477-x","article-title":"Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets","volume":"89","author":"Tham","year":"2015","journal-title":"Arch Toxicol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1152\/physrev.00043.2016","article-title":"Understanding key mechanisms of exercise-induced cardiac protection to mitigate disease: current knowledge and emerging concepts","volume":"98","author":"Bernardo","year":"2018","journal-title":"Physiol Rev"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1172\/JCI25397","article-title":"Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction","volume":"116","author":"Perrino","year":"2006","journal-title":"J Clin Invest"},{"key":"B46","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1161\/ATVBAHA.109.201988","article-title":"PI3K(p110 Alpha) protects against myocardial infarction-induced heart failure: identification of PI3K-regulated miRNA and mRNA","volume":"30","author":"Lin","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1007\/s00125-012-2720-0","article-title":"Enhanced phosphoinositide 3-kinase(p110\u03b1) activity prevents diabetes-induced cardiomyopathy and superoxide generation in a mouse model of diabetes","volume":"55","author":"Ritchie","year":"2012","journal-title":"Diabetologia"},{"key":"B48","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1161\/HYPERTENSIONAHA.109.149344","article-title":"Role of phosphoinositide 3-kinase {alpha}, protein kinase C, and L-type Ca2+ channels in mediating the complex actions of angiotensin II on mouse cardiac contractility","volume":"56","author":"Liang","year":"2010","journal-title":"Hypertension"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1161\/01.RES.0000223321.34482.8c","article-title":"Insulin-like growth factor-1 and PTEN deletion enhance cardiac L-type Ca2+ currents via increased PI3Kalpha\/PKB signaling","volume":"98","author":"Sun","year":"2006","journal-title":"Circ Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1161\/CIRCRESAHA.117.310183","article-title":"PI3K and calcium signaling in cardiovascular disease","volume":"121","author":"Ghigo","year":"2017","journal-title":"Circ Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2353\/ajpath.2009.090126","article-title":"Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation","volume":"175","author":"Pretorius","year":"2009","journal-title":"Am J Pathol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1021\/ml5005014","article-title":"Discovery of a novel series of thienopyrimidine as highly potent and selective PI3K inhibitors","volume":"6","author":"Han","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"B53","doi-asserted-by":"publisher","first-page":"108011","DOI":"10.1016\/j.bioorg.2024.108011","article-title":"Current developments in PI3K-based anticancer agents: designing strategies, biological activity, selectivity, structure-activity correlation, and docking insight","volume":"154","author":"Sk","year":"2025","journal-title":"Bioorg Chem"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1056\/NEJMoa2501796","article-title":"Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer","volume":"393","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"key":"B56","year":"2026"},{"key":"B57","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jaccao.2024.02.005","article-title":"Anthracycline cardiotoxicity induces progressive changes in myocardial metabolism and mitochondrial quality control: novel therapeutic target","volume":"6","author":"D\u00edaz-Guerra","year":"2024","journal-title":"JACC CardioOncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1406247","DOI":"10.3389\/fphar.2024.1406247","article-title":"An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity","volume":"15","author":"Xie","year":"2024","journal-title":"Front Pharmacol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"6084","DOI":"10.1002\/cam4.1886","article-title":"Doxorubicin-induced heart failure in cancer patients: a cohort study based on the Korean National Health Insurance Database","volume":"7","author":"Kim","year":"2018","journal-title":"Cancer Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"19","author":"Zamorano","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"B62","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1040-8428(97)10007-5","article-title":"Anthracycline-induced cardiotoxicity in children and young adults","volume":"27","author":"Giantris","year":"1998","journal-title":"Crit Rev Oncol Hematol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1001\/jama.1991.03470120074036","article-title":"Cardiac toxicity 4 to 20 years after completing anthracycline therapy","volume":"266","author":"Steinherz","year":"1991","journal-title":"JAMA"},{"key":"B64","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3322\/caac.21341","article-title":"Cardiotoxicity of anticancer treatments: epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B65","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/978-3-030-43032-0_15","article-title":"Anthracycline-induced cardiotoxicity: causes, mechanisms, and prevention","volume":"1257","author":"Bhagat","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"B67","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3904\/kjim.2016.017","article-title":"Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity","volume":"31","author":"Chung","year":"2016","journal-title":"Korean J Intern Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","article-title":"Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities","volume":"64","author":"Vejpongsa","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e0158376","DOI":"10.1371\/journal.pone.0158376","article-title":"Deficiency in cardiolipin reduces doxorubicin-induced oxidative stress and mitochondrial damage in human B-lymphocytes","volume":"11","author":"Aryal","year":"2016","journal-title":"PLoS One"},{"key":"B70","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.mito.2016.07.005","article-title":"Cardiac cytochrome c and cardiolipin depletion during anthracycline-induced chronic depression of mitochondrial function","volume":"30","author":"Pereira","year":"2016","journal-title":"Mitochondrion"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e16920","DOI":"10.7759\/cureus.16920","article-title":"Delayed onset anthracycline-associated cardiotoxicity presenting as acute decompensated heart failure seven years after chemotherapy completion","volume":"13","author":"Tran","year":"2021","journal-title":"Cureus"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.3390\/ijms23031912","article-title":"Mitochondrial-targeted therapy for doxorubicin-induced cardiotoxicity","volume":"23","author":"Wu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B73","doi-asserted-by":"publisher","first-page":"106632","DOI":"10.1016\/j.biocel.2024.106632","article-title":"Iron metabolism in doxorubicin-induced cardiotoxicity: from mechanisms to therapies","volume":"174","author":"Ye","year":"2024","journal-title":"Int J Biochem Cell Biol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1000120","DOI":"10.4172\/2329-9517.1000120","article-title":"Neuregulin1 improved cardiac function in doxorubicin-treated mice with cardiomyocyte-specific over expression of a dominant-negative PI3Kp110\u03b1","volume":"1","author":"Bian","year":"2013","journal-title":"J Cardiovasc Dis Diagn"},{"key":"B75","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","article-title":"Anthracycline cardiotoxicity in adult cancer patients: JACC: cardiooncology state-of-the-art review","volume":"6","author":"Camilli","year":"2024","journal-title":"JACC CardioOncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1038\/ncomms6705","article-title":"The small-molecule BGP-15 protects against heart failure and atrial fibrillation in mice","volume":"5","author":"Sapra","year":"2014","journal-title":"Nat Commun"},{"key":"B77","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2337\/db20-0653","article-title":"Novel lipid species for detecting and predicting atrial fibrillation in patients with type 2 diabetes","volume":"70","author":"Tham","year":"2021","journal-title":"Diabetes"},{"key":"B78","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41392-022-01149-x","article-title":"Signaling pathways in obesity: mechanisms and therapeutic interventions","volume":"7","author":"Wen","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B79","doi-asserted-by":"publisher","first-page":"ehag546","DOI":"10.1093\/eurheartj\/ehag546","article-title":"Hypertension with defective IGF1R-PI3K signalling may trigger atrial cardiomyopathy, atrial fibrillation, and stroke","author":"McMullen","year":"2026","journal-title":"Eur Heart J"},{"key":"B80","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s00204-020-02709-2","article-title":"Clusterin is regulated by IGF1-PI3K signaling in the heart: implications for biomarker and drug target discovery, and cardiotoxicity","volume":"94","author":"Bass-Stringer","year":"2020","journal-title":"Arch Toxicol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/s12885-015-1407-6","article-title":"The prevention, detection and management of cancer treatment-induced cardiotoxicity: a meta-review","volume":"15","author":"Conway","year":"2015","journal-title":"BMC Cancer"},{"key":"B83","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40959-019-0054-5","article-title":"Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors","volume":"5","author":"Bansal","year":"2019","journal-title":"Cardiooncology"},{"key":"B84","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1146\/annurev-pharmtox-030620-104842","article-title":"Preventing and treating anthracycline cardiotoxicity: new insights","volume":"61","author":"Sawicki","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1161\/CIRCULATIONAHA.121.054698","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): extended follow-up of a 2\u2009\u00d7\u20092 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"143","author":"Heck","year":"2021","journal-title":"Circulation"},{"key":"B86","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J Clin Oncol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"101332","DOI":"10.1016\/j.ijcha.2023.101332","article-title":"Doxorubicin-induced cardiotoxicity and risk factors","volume":"50","author":"Belger","year":"2024","journal-title":"Int J Cardiol Heart Vasc"},{"key":"B88","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1200\/JCO.2005.02.3879","article-title":"Dexrazoxane-associated risk for acute myeloid leukemia\/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin\u2019s disease","volume":"25","author":"Tebbi","year":"2007","journal-title":"J Clin Oncol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/s41598-021-80984-4","article-title":"Fenofibrate attenuates doxorubicin-induced cardiac dysfunction in mice via activating the eNOS\/EPC pathway","volume":"11","author":"Huang","year":"2021","journal-title":"Sci Rep"},{"key":"B90","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.freeradbiomed.2015.05.028","article-title":"Sulforaphane protects the heart from doxorubicin-induced toxicity","volume":"86","author":"Singh","year":"2015","journal-title":"Free Radic Biol Med"},{"key":"B91","doi-asserted-by":"publisher","first-page":"111155","DOI":"10.1016\/j.cbi.2024.111155","article-title":"Anethole alleviates doxorubicin-induced cardiac and renal toxicities: insights from network pharmacology and animal studies","volume":"401","author":"Al-Ali","year":"2024","journal-title":"Chem Biol Interact"},{"key":"B92","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jtcvs.2010.07.097","article-title":"Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function","volume":"142","author":"Hiona","year":"2011","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B93","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1161\/CIRCRESAHA.123.323346","article-title":"Exercise inhibits doxorubicin-induced cardiotoxicity via regulating B cells","volume":"134","author":"Wang","year":"2024","journal-title":"Circ Res"},{"key":"B94","doi-asserted-by":"publisher","first-page":"605993","DOI":"10.3389\/fcvm.2021.605993","article-title":"Exercise training preserves myocardial strain and improves exercise tolerance in doxorubicin-induced cardiotoxicity","volume":"8","author":"Gomes-Santos","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"7572","DOI":"10.1002\/cam4.4283","article-title":"Exercise intervention decreases acute and late doxorubicin-induced cardiotoxicity","volume":"10","author":"Wang","year":"2021","journal-title":"Cancer Med"},{"key":"B96","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s43018-020-0039-1","article-title":"A small-molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathy","volume":"1","author":"Amgalan","year":"2020","journal-title":"Nat Cancer"},{"key":"B97","year":"2025"},{"key":"B98","year":"2026"},{"key":"B99","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jaccao.2024.07.010","article-title":"Preventing cardiac damage in patients treated for breast cancer and lymphoma: the PROACT clinical trial","volume":"6","author":"Austin","year":"2024","journal-title":"JACC CardioOncol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"e997","DOI":"10.1161\/CIR.0000000000000679","article-title":"Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association","volume":"139","author":"Gilchrist","year":"2019","journal-title":"Circulation"},{"key":"B101","doi-asserted-by":"publisher","first-page":"171245","DOI":"10.1016\/j.peptides.2024.171245","article-title":"Tirzepatide protects against doxorubicin-induced cardiotoxicity by inhibiting oxidative stress and inflammation via PI3K\/Akt signaling","volume":"178","author":"Chen","year":"2024","journal-title":"Peptides"},{"key":"B102","doi-asserted-by":"publisher","first-page":"100136","DOI":"10.1016\/j.crtox.2023.100136","article-title":"Activation of PI3K\/Akt mediates the protective effect of diallyl trisulfide on doxorubicin induced cardiac apoptosis","volume":"5","author":"Wen","year":"2023","journal-title":"Curr Res Toxicol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1042\/CS20170063","article-title":"Phosphoinositide 3-kinase (p110\u03b1) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction","volume":"131","author":"Prakoso","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"B104","doi-asserted-by":"publisher","first-page":"H840","DOI":"10.1152\/ajpheart.00632.2019","article-title":"Gene therapy targeting cardiac phosphoinositide 3-kinase (p110\u03b1) attenuates cardiac remodeling in type 2 diabetes","volume":"318","author":"Prakoso","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B105","article-title":"Clearing the fog: the potential of plasmalogens in mitigating chemotherapy-induced cognitive impairment","author":"Isobel","year":"2024"},{"key":"B106","doi-asserted-by":"publisher","first-page":"7159","DOI":"10.1007\/s12035-019-1589-z","article-title":"Chemotherapy-induced cognitive impairment is associated with increased inflammation and oxidative damage in the hippocampus","volume":"56","author":"Bagnall-Moreau","year":"2019","journal-title":"Mol Neurobiol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"118581","DOI":"10.1016\/j.biopha.2025.118581","article-title":"Cognitive dysfunction in chemobrain: molecular mechanisms and therapeutic implications","volume":"192","author":"Kim","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"B108","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.bbalip.2017.12.003","article-title":"Distinct lipidomic profiles in models of physiological and pathological cardiac remodeling, and potential therapeutic strategies","volume":"1863","author":"Tham","year":"2018","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"B109","doi-asserted-by":"publisher","first-page":"100273","DOI":"10.1016\/j.jmccpl.2024.100273","article-title":"An optimized plasmalogen modulating dietary supplement provides greater protection in a male than female mouse model of dilated cardiomyopathy","volume":"11","author":"Belkin","year":"2025","journal-title":"J Mol Cell Cardiol Plus"},{"key":"B110","year":"2025"},{"key":"B111","year":"2024"},{"key":"B112","year":"2025"},{"key":"B113","year":"2023"},{"key":"B114","year":"2020"},{"key":"B115","year":"2023"},{"key":"B116","year":"2023"},{"key":"B117","year":"2024"},{"key":"B118","year":"2025"},{"key":"B119","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","article-title":"Cardiotoxicity of anthracyclines","volume":"7","author":"Cardinale","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"B120","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3390\/medicina61040709","article-title":"Overview of oncology: drug-induced cardiac toxicity","volume":"61","author":"Kundnani","year":"2025","journal-title":"Medicina (Kaunas)"},{"key":"B121","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41580-020-0255-7","article-title":"ERK signalling: a master regulator of cell behaviour, life and fate","volume":"21","author":"Lavoie","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1002\/cncr.28864","article-title":"The MAPK pathway across different malignancies: a new perspective","volume":"120","author":"Burotto","year":"2014","journal-title":"Cancer"},{"key":"B123","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1021\/acsptsci.5c00084","article-title":"Exploring phosphatase and tensin homologue deleted on chromosome ten (PTEN) as a potential therapeutic target for cardiac hypertrophy","volume":"8","author":"Jha","year":"2025","journal-title":"ACS Pharmacol Transl Sci"},{"key":"B124","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40001-024-01677-y","article-title":"TFR1 knockdown alleviates iron overload and mitochondrial dysfunction during neural differentiation of Alzheimer\u2019s disease-derived induced pluripotent stem cells by interacting with GSK3B","volume":"29","author":"Kang","year":"2024","journal-title":"Eur J Med Res"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1161\/01.ATV.0000073832.49290.B5","article-title":"Endothelial progenitor cells: mobilization, differentiation, and homing","volume":"23","author":"Hristov","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"100478","DOI":"10.1016\/j.jmccpl.2025.100478","article-title":"Generation and evaluation of a novel PI3K-targeting gene therapy in the failing mouse heart and healthy sheep heart","volume":"13","author":"Bass-Stringer","year":"2025","journal-title":"J Mol Cell Cardiol Plus"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1891148\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:08:27Z","timestamp":1787562507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1891148\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":126,"alternative-id":["10.3389\/fcvm.2026.1891148"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1891148","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"article-number":"1891148"}}